[February 24, 2017] |
|
$11.04 Billion Next Generation Cancer Diagnostics Market 2017 By Technology, Application, Cancer Type, Function Companion Diagnostics - Forecasts to 2025 - Research and Markets
Research and Markets has announced the addition of the "Next
Generation Cancer Diagnostics Market Size & Forecasts By Technology
(NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type
(Lung, Breast), By Function Companion Diagnostics, And Trend Analysis,
2013 - 2024" report to their offering.
The global next generation cancer diagnostics market is anticipated to
reach USD 11.04 billion by 2024. Key drivers for this vertical include
rising advancement in genomics and proteomics-based research coupled
with increasing prevalence of oncology disorders.
A rise in the number of oncological research projects to elucidate
tumorigenesis and the underlying mechanisms, consequently raising the
demand for serial sampling, diagnosis, and therapeutic manipulation, is
a growth rendering driver of this market.
Further Key Findings from the Study Suggest:
-
The qPCR & multiplexing segment captured the largest market share in
2015 owing to the presence of a wide product portfolio serving
numerous applications in oncology R&D
-
Next generation sequencing services and solutions for oncology
applications are anticipated to be the fastest growing segment
-
Oncology diagnostics in biomarker discovery is expected witness growth
as it subsequently facilitates drug designing and identification of
novel targets against tumors
-
On the basis of cancer type, this vertical is segmented into lung,
breast, colorectal, cervical, and other forms of cancer
-
Research projects to establish the therapeutic index of anticancer
cytotoxic drugs are one of the key factors responsible for expected
growth
-
North America dominated the market with respect to revenue generation
in 2014 due to concerted efforts directed toward the development of
next generation sequencing technology and companion diagnostics in
personalized medicine
Market Dynamics
Market driver analysis
-
Exponentially decreasing cost of genetic sequencing
-
Development of cluster chip technology and potential applications of
CTC (News - Alert) in cancer management
-
Rising demand for preventive medicine & companion diagnostics
-
Growing cancer incidence
Market restraint analysis
-
Requirement of expensive laboratory set-up for implementation of novel
tests
Key Opportunities
Some of the key players contributing significantly to the next
generation cancer diagnostics market are
-
Janssen Global Services, LLC
-
Novartis AG
-
F. Hoffmann-La Roche Ltd
-
Koninklijke Philips (News - Alert) N.V.
-
Abbott
-
GE Healthcare
-
Thermo Fisher Scientific, Inc.
-
Agilent Technologies (Dako)
-
Illumina, Inc.
-
Qiagen
-
Cepheid
-
Opko Health, Inc.
-
Hologic, Inc (Gen-Probe)
-
Perkin Elmer, Inc.
-
Sysmex Corporation
-
Myriad Genetics, Inc.
-
Almac Group
-
Exosome Diagnostics, Inc.
-
Genomic Health, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/l66b52/next_generation
View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005695/en/
[ Back To TMCnet.com's Homepage ]
|